Pulmonary Drug Delivery Devices Market

Pulmonary Drug Delivery Devices Market Size (2022 to 2027)

The global pulmonary drug delivery devices market size was worth USD 38.1 billion in 2022. This value is expected to reach USD 47.0 billion by 2027, growing at a CAGR of 4.3% from 2022 to 2027.

Pulmonary drug delivery devices are specific systems used to deliver drugs to the lung to treat diseases of the respiratory tract. They are extensively monitored, as the process can be fatal if not performed correctly. This drug delivery method is often preferred because of its non-invasive nature and the fact that the process gives faster results due to speedier administration. The benefits of large surface area for absorption, high blood circulation, and higher permeability rate have attracted many takers for the method.

MARKET DRIVERS:

The rise in population, substantial growth in the geriatric population, and a rise in the number of chronic diseases like tuberculosis, bronchitis, and chronic obstructive pulmonary disease have helped the pulmonary drug delivery devices market.

The global pulmonary drug delivery devices market is currently divided into nebulizers, dose inhalers, powder inhalers, etc. And these products today are readily available in hospitals, clinics, pharmacies, etc. But the growing market for medical health and the ever-increasing possibilities in the online market for the same has helped the market reach out to a broader audience. Many attempts are also being made to make the policies more streamlined and more affordable by the government by investing in this industry's research.

The limitation of other drug delivery systems compared to the benefit of the pulmonary drug delivery system, like the better penetrability of the drug, minimum dosage requirement, and growing technological advancements, have helped the global pulmonary drug delivery devices market grow worldwide scale.

MARKET RESTRAINTS:

However, a few hindrances are a part of the global pulmonary drug delivery devices market. Its high prices, the need for medically trained supervisors, and many regulatory policies must be followed.

COVID-19's Effect on the global pulmonary drug delivery devices market:

As of Feb 2021, Coronavirus has infected over 4.4 million people in 215 countries and territories, resulting in nearly 300,000 deaths. We estimate that the share of infectious diseases has increased due to the COVID-19 outbreak and that this segment will rise significantly during the forecast period. The drug delivery market has developed rapidly due to COVID-19, and it is projected to expand at a substantial pace between 2020 and 2021. In several nations, the COVID-19 outbreak has been growing at an exponential rate. This has necessitated improved patient care and the availability of additional nutritional/immunity assistance, devices such as inhalers and nebulizers to virus-affected patients. This has led to increased adoption of drugs, some of the devices for improvement of patient care. There are many drugs, devices, and vaccines in different clinical trials for treating COVID-19 that are expected to be released in the coming months/years under emergency use authorization guidelines. As a result, Pulmonary Drug Delivery Devices have positive growth during the forecast period.

REPORT COVERAGE;

This research report on the global pulmonary drug delivery devices market has been segmented and sub-segmented based on the product, application, distribution channel, and region.

Pulmonary Drug Delivery Devices Market - By Product:

• Dry Powder Inhalers
  • Single-Dose Inhalers
  • Multi-Dose Inhalers
• Metered Dose Inhalers
  • Manually-Actuated Pressurized Inhaler
  • Breath-Actuated Pressurized Inhaler
• Nebulizers
  • Jet Nebulizers
  • Ultrasonic Wave Nebulizers
  • Vibrating Mesh Nebulizers

The Metered Dose Inhalers (MDI) segment had the highest market share of 66.7 percent based on the product. The high acceptance rate of these devices in developing regions such as the Asia Pacific and Latin America and the involvement of global key players in the production of novel MDIs contribute to the segment's revenue. The Dry Powder Inhaler (DPI) market is expected to rise at a healthy pace in the coming years. End users are likely to use these inhalers more due to benefits such as cost-effectiveness, ease of administration, and preparation time, among others.

Pulmonary Drug Delivery Devices Market - By Application:

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Others

Based on the applications, Chronic Obstructive Pulmonary Disease is regarded as the most substantial value in market share in the forecast period. COPD's exponential rise can be attributed to the disease's high incidence and mortality rates. Revenue created by this segment is growing due to favorable reimbursement policies for COPD treatment and an increase in the number of government and non-government organizations that provide COPD treatment.

The asthma segment had the highest market share. Asthma management is thought to begin with an effective inhalation therapy that involves DPIs and MDIs. For many people who have asthma, the demand for and use of asthma management devices such as MDIs and DPIs, boost this application's growth.

Pulmonary Drug Delivery Devices Market - By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• E-commerce

By distribution channel, the hospital pharmacies segment dominated the global pulmonary drug delivery device market. Patients prefer hospital pharmacies because they have extensive treatments, care, quick reimbursements, and insurance policies. Furthermore, the segment's growth is expected to be supported by a rise in hospitalizations.

However, the e-commerce section is likely to expand with a remarkable growth rate in the coming years. Various factors, such as enhanced healthcare infrastructure in emerging regions and ease of purchase compared to retail or hospital pharmacies, have significantly helped the growth of this distribution channel.

Pulmonary Drug Delivery Devices Market - By Region:

• North America
  • The United States
  • Canada
  • Rest of North America
• Europe
  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Rest of EU
• Asia Pacific
  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of LATAM
• Middle East
• Africa

The market for these pulmonary drug delivery devices has been established in developed regions like North America and Europe. North America accounted for the majority of PDDS in 2019, with a market value of USD 14.9 billion. The rising prevalence of diseases like COPD (Chronic Obstructive Pulmonary Disease) and asthma is likely to boost the growth rate of the market. As the number of patients affected by these diseases grows, so does the demand for diagnostic devices like PDDS (Pulmonary Drug Delivery Systems), boosting the region's growth. Furthermore, major pharmaceutical and medical device companies in the area and advanced healthcare infrastructure, an aging population, high disposable income, and lifestyle changes contribute to the market's overall growth in North America.

The Asia Pacific has soon been catching on owing to the growing focus on healthcare in this region. Due to the high prevalence of COPD, which indicates a significant socioeconomic burden in this area, the Asia Pacific region is expected to rise at an exponential rate of 6.2 percent. The continuous rise in the number of asthmatic and allergic rhinitis patients is another major factor expected to boost PDDS market demand in the Asia Pacific region over the forecast period. Additionally, an increase in the number of supporting non-governmental organizations, such as the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI), is expected to raise patient awareness about respiratory treatment disorders, resulting in market development. The Asia Pacific region's growth is also expected to be aided by an increase in R&D activities by key market players to develop novel respiratory devices.

KEY MARKET PLAYERS:

Companies leading the global pulmonary drug delivery devices market profiled in this report are AstraZeneca PLC, Boehringer Ingelheim Gmbh, GlaxoSmithKline plc, Clement Clarke International, Briggs Healthcare, Novartis AG, Koninklijke Philips N.V., 3M Company, and Actelion Pharmaceuticals Ltd.

RECENT MARKET HAPPENINGS:

• In February 2020, IO Biotech announced the positive outcome of Phase 2 randomized trial interim analysis in first-line non-small cell lung cancer.
• In February 2020, Novartis announced a collaboration to develop a drug to treat Visceral Leishmaniasis.
• In February 2020, Novartis won EC approval for Anti-VEGF Treatment Beovu. It is a next-generation Anti-VEGF treatment for WET AMD, a leading cause of blindness throughout the world.
• In February 2020, Novartis announced MET inhibitor lapatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review.
• In February 2020, British drugmaker GSK is to collaborate with CEPI to develop a coronavirus vaccine. The company has worked on coronavirus breakout to develop a vaccine.
• In February 2020, Merck's Recarbrio got an FDA priority review for New Indication. The company has announced that the FDA accepted that the supplement's new drug application sought approval of its new antibacterial injection Recarbrio for a further indication. 
• In November 2019, Sunovion resubmitted New Drug Application for Apomorphine sublingual film. NDA's resubmission to the US FDA for apomorphine to treat motor fluctuations experienced by people with Parkinson's Disease.
• In October 2019, PsychoGenics Announcesd Milestones Associated with Sunovion's Advancing Pipeline. PGI Drug Discovery LLC (PsychoGenics) announced that it had received milestone payments from Sunovion Pharmaceuticals Inc. (Sunovion) associated with the advancement of two compounds into clinical testing - SEP-378614 and SEP-380135
• In May 2019, Sunovion and PsychoGenics announced that SEP-363856 received FDA breakthrough therapy designation to treat people with Schizophrenia.
• In December 2017, Medtronic manufactured an implantable system Remodulin (ISR), which gained FDA approval to treat pulmonary arterial hypertension patients (PAH).